Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first. Each row links to its question's own page, which gathers every review that asked it, however worded; see the questions asked by more than one review.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum Acupuncture for acute hordeolum (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Proportion of participants who lost two or more lines of best‐corrected visual acuity (BCVA) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D) Laser‐assisted subepithelial keratectomy (LASEK) versus laser‐assisted in‐situ keratomileusis (LASIK) for… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Postoperative pain score: 1 year · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D) Laser‐assisted subepithelial keratectomy (LASEK) versus laser‐assisted in‐situ keratomileusis (LASIK) for… (2017) · Cochrane | no estimate extracted | NR | No studies |
All‐cause mortalitye · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Strokeg · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Myocardial infarction · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE‐related mortalitya · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Outcomes · people with confirmed diagnosis of Marfan syndrome Beta‐blockers for preventing aortic dissection in Marfan syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Proportion of participants requiring secondary procedures · children with congenital nasolacrimal duct obstruction (NLDO) Probing for congenital nasolacrimal duct obstruction (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Complications · children with congenital nasolacrimal duct obstruction (NLDO) Probing for congenital nasolacrimal duct obstruction (2017) · Cochrane | no estimate extracted | NR | No studies |
Adverse events · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Leaving the study early · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Economic costs · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(b) Change in the frequency of defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(c) Change in straining at defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(d) Change in the frequency of lumpy or hard stools · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(e) Change in the frequency of manual manoeuvres to facilitate defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Need for rescue medication · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Presence of antipsychotic‐related constipation complications such as bowel obstruction · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Quality of life (changed to any extent) · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Adverse events · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Leaving the study early · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Economic costs · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(b) Change in the frequency of defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(c) Change in straining at defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(d) Change in the frequency of lumpy or hard stools · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(e) Change in the frequency of manual manoeuvres to facilitate defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(b) Change in the frequency of defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Need for rescue medication · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Presence of antipsychotic‐related constipation complications such as bowel obstruction · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Quality of life (changed to any extent) · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Leaving the study early · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Economic costs · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(c) Change in straining at defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(d) Change in the frequency of lumpy or hard stools · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
(e) Change in the frequency of manual manoeuvres to facilitate defecation · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Need for rescue medication · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Presence of antipsychotic‐related constipation complications such as bowel obstruction · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Quality of life (changed to any extent) · antipsychotic‐related constipation Pharmacological treatment for antipsychotic‐related constipation (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR *CI: Confidence interval · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Uptake ‐ not measured · General population for prevalence outcomes. Adult smokers for tobacco consumption outcomes. Tobacco packaging design for reducing tobacco use (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Relapse ‐ not measured · General population for prevalence outcomes. Adult smokers for tobacco consumption outcomes. Tobacco packaging design for reducing tobacco use (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cessation ‐ not measured · General population for prevalence outcomes. Adult smokers for tobacco consumption outcomes. Tobacco packaging design for reducing tobacco use (2017) · Cochrane | no estimate extracted | NR | No studies |
Proportion of participants undergoing retreatment for urinary stones · children with idiopathic urinary calculi treated with shockwave lithotripsy Medical and dietary interventions for preventing recurrent urinary stones in children (2017) · Cochrane | no estimate extracted | NR | No studies |
Adverse events · people with patellofemoral pain syndrome Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Adverse events ‐ not measured · people with patellofemoral pain syndrome1 Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Knee pain (short term: < 3 months) · people with patellofemoral pain syndrome Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Knee pain (longer term: > 3 months) · people with patellofemoral pain syndrome Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Knee function (longer term: > 3 months) · people with patellofemoral pain syndrome Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Change in the prevalence of cataract blindness · people with vision impairment caused by cataract Interventions to improve access to cataract surgical services and their impact on equity in low‐ and… (2017) · Cochrane | no estimate extracted | NR | No studies |